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The Netherlands; and La Jolla, CalifWhat is already known about this topic? Randomized controlled trial results support the efficacy and tolerability of
recombinant human C1 esterase inhibitor (rhC1INH) at 50 IU/kg for the treatment of acute hereditary angioedema attacks.
What does this article add to our knowledge?
 rhC1INH efficacy is maintained for the treatment of subsequent attacks.
 Single doses of rhC1INH are effective in most of the cases.
 Relapse rates were low.
 No increase in the number of adverse events or change in the adverse event profile was observed with rhC1INH
treatments for repeat attacks.
How does this study affect current management guidelines? The present study supports the repeated use of rhC1INH
for the treatment of recurring attacks in patients with hereditary angioedema.BACKGROUND: Hereditary angioedema (HAE) caused by a
deficiency in functional C1 esterase inhibitor (C1INH) is
characterized by recurrent episodes of cutaneous and/or
mucosal/submucosal tissue swelling affecting multiple anatomic
locations. Previous studies demonstrated efficacy of recombinant
human C1INH (rhC1INH) for acute HAE attacks.
OBJECTIVE: This study evaluated the efficacy and safety of
rhC1INH (50 IU/kg) for the treatment of multiple HAE attacks
in an open-label extension study.
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RESULTS: Forty-four patients received rhC1INH, and a single
dosewas administered for 215 of 224 (96%) attacks.Median time to
beginningof symptomrelief basedonTEQfor thefirst 5 attackswas
75.0 (95%CI, 69-89) minutes, ranging from 62.5 (95%CI, 48-90)
to 134.0 (95% CI, 32-119) minutes. Median time to minimal
symptomsusingTEQ for thefirst 3 attackswas 303.0 (95%CI, 211-
367) minutes. rhC1INH was well tolerated. There were no
discontinuations due to adverse events. No thrombotic or
anaphylactic events were reported, and repeat rhC1INH treatments
were not associated with neutralizing anti-C1INH antibodies.
CONCLUSIONS: A single 50-IU/kg dose rhC1INH was effective
for improving symptoms of an HAE attack with sustained efficacy
for treatment of subsequent attacks. rhC1INH had a positive
safety profile throughout the study. This study supports repeated
use of rhC1INH over time in patients with HAE attacks.  2015
The Authors. Published by Elsevier Inc. on behalf of the American
Academy of Allergy, Asthma & Immunology. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/) (J Allergy Clin
Immunol Pract 2015;3:417-23)
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Hereditary angioedema (HAE), a rare genetic disorder, has a
prevalence of around 1 in 50,000.1 With deficiency of functional
C1 esterase inhibitor (C1INH), overproduction of bradykinin
results in increased vascular permeability and acute angioedema
attacks. Attacks of HAE are episodic, which vary widely among
patients. The extremities, face, and abdomen are the most
commonly involved sites. Oropharyngeal-laryngeal swelling,417
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C1INH- C1 Esterase inhibitor
HAE- Hereditary angioedema
HRI- Host-related impurities
IS- Investigator ScoreOLE- Open-label extension
rhC1INH- Recombinant human C1 esterase inhibitor
pdC1INH- Purified human plasmaederived C1INHRCT- Randomized controlled trial
TEQ- Treatment Effect Questionnaire
VAS- Visual analog scalewhile less frequent, can be life-threatening. More than 50% of
the patients with HAE have at least a episode of laryngeal
swelling in their lifetime.2 HAE is associated with significant
health burden.3,4 Current guidelines recommend that all patients
with HAE have access to medicine for the treatment of acute
attacks.5,6
C1INH replacement therapy is a logical approach to HAE
management, and purified human plasmaederived C1INH
(pdC1INH) products have been approved for either prevention
or treatment of acute attacks.7 However, these products carry a
potential risk for transmission of human pathogenic viruses and
prions, and have been associated with thrombotic events.8 In
addition, shortages of available donor plasma sources can limit
production.
Recombinant human C1INH (rhC1INH) is an important
alternative treatment option to pdC1INH products that can
address potential risks associated with blood-derived pathogens.
In addition, the transgenic rabbit platform ensures a reliable and
scalable supply of a product with uniform quality.9 The re-
combinant protein, with a sequence identical to that of human
C1INH, is expressed in mammary glands of transgenic rabbits
and purified from milk. Because rhC1INH retains the specificity
of human pdC1INH toward its target proteases, the mode of
action is identical. Differences in the glycosylation of rhC1INH
and pdC1INH do not affect the specificity of rhC1INH to
inhibit its target proteases.10 Population pharmacokinetic
modeling supports a dosing scheme of 50 IU/kg, which achieves
C1INH levels above the lower level of the normal range (0.7 U/
mL) in at least 94% of the patients.11 These plasma levels are
required to achieve complete inhibition of inflammatory cascades
as demonstrated by continued C4 cleavage and higher C4 b/c
concentrations at lower doses.12
Previous randomized controlled trials (RCTs) indicate that
rhC1INH at 50 and 100 IU/kg is a highly effective and well-
tolerated treatment for acute HAE attacks.13 Furthermore,
open-label extension (OLE) studies demonstrated that efficacy
was maintained for subsequent acute HAE attacks.14,15 For 119
patients treated for 362 attacks in these 2 studies, more than
80% of repeat attacks responded within 4 hours and most of the
patients required only a single dose of rhC1INH. There was no
increase in the incidence of adverse events or induction of
neutralizing antibodies. The present pivotal study evaluated a
dose of 50 IU/kg in a larger population of patients with HAE in
an RCT followed by an OLE phase. Results of the RCT have
been published separately.16 This analysis focuses on the efficacy
and safety of rhC1INH for repeated treatment of multiple at-
tacks in the OLE phase.METHODS
Study design
This study was the OLE portion of an international RCT (no.
NCT01188564). In the OLE phase, patients were treated at 8
centers in the United States and 1 site each in Bulgaria, Israel, Italy,
Macedonia, Poland, Romania, and Serbia. All study activities were
conducted in compliance with the Declaration of Helsinki and
approved by local institutional review boards.
The methods for the RCT of the study have been previously
reported.16 All patients who were treated in the randomized phase
were eligible for participation in the OLE phase. All patients met the
inclusion and exclusion criteria of the RCT study. They were 13
years or older at US sites and 18 years or older at other sites.
Exclusion criteria included acquired C1INH deficiency and a
medical history of rabbit allergy.
Patients who presented to a study center within 5 hours of the
onset of an HAE attack were eligible to receive rhC1INH if their
visual analog scale (VAS) overall severity score was 50 mm or more
(0 mm ¼ no symptoms; 100 mm ¼ extremely disabling), with no
evidence of spontaneous regression of angioedema symptoms be-
tween presentation to the clinic and infusion of study medication.
For patients with multiple attack locations, the primary attack
location was defined as the location with the highest overall VAS
score at baseline.
Attacks were treated with 1 intravenous injection of rhC1INH at
a dose of 50 IU/kg for patients weighing less than 84 kg or 4200 IU
for patients weighing 84 kg or more. An additional dose was allowed
1 hour after initial dosing if warranted by the patients’ clinical re-
sponses and at the discretion of the investigator. Patients remained
under observation for up to 6 hours (see Figure 1 for full schedule of
study assessments) and then were sent home with Treatment Effect
Questionnaire (TEQ) and VAS forms to record the severity of
symptoms at the 8, 12, and 24-hour time points and a diary to
record the time at which there was complete resolution of symptoms.
Adverse events and concomitant medications were also recorded.
Phone calls were scheduled at approximately 24 hours and at day 4.
Follow-up visits were planned for days 7, 28, and 90. The efficacy
assessment forms and diary were collected at day 7.
Study endpoints
The severity of the angioedema attack was assessed by patients
using the TEQ (see this article’s Online Repository at www.jaci-
inpractice.org for detailed questions) and the VAS and by physi-
cians using a 6-point ordinal scale (Investigator Score [IS]) for each
symptomatic anatomical location at 15-minute intervals for 2 hours,
followed by 30-minute intervals through 6 hours.
The primary efficacy endpoint was the time to beginning of relief
of symptoms at the primary attack location (based on questions 1
and 2 of the TEQ, with persistence of improvement maintained at
the next assessment time). Time to onset of symptom relief was also
assessed on the basis of VAS score decrease of 20 mm or more or IS
score decrease by at least 1 point from baseline at the primary attack
location. The secondary efficacy endpoint was the time to minimal
symptoms at all affected locations for the first 3 attacks, and was
defined as the time point at which patients responded with a “Yes”
to question 3 of the TEQ. This was assessed only for the first 3
treated attacks because patients were typically discharged 2 hours
after rhC1INH administration, and the endpoint usually was
reached after this time. Time to minimal symptoms was also assessed
using the VAS (VAS score <20 mm at all affected locations) and the
IS (IS 1).
FIGURE 1. Schedule of assessments.
TABLE I. Demographic and HAE attack characteristics
Characteristic OLE intent-to-treat population (N [ 44)
Age (y), mean  SD 39.7  14.4
Sex, n (%)
Female 26 (59)
Male 18 (41)
BMI (kg/m2), mean  SD 28.7  8.0
Weight (kg), mean  SD 82.5  23.1
Race, n (%)
White 42 (95)
Black/African American 2 (5)
Ethnicity, n (%)
Hispanic/Latino descent 1 (2)
Primary attack location, no. of attacks (%)
Abdominal 101 (45)
Peripheral 92 (41)
Facial 18 (8)
Oropharyngeal-laryngeal 8 (4)
Urogenital 5 (2)
Total no. of attacks 224
Baseline VAS score (mm), mean  SD
Attack 1* 77.9  13.8
Attack 2 78.6  16.0
Attack 3 76.9  14.1
Attack 4 76.4  11.3
Attack 5 77.8  13.8
BMI, Body mass index.
*Attack 1 from OLE phase only.
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was assessed for the incidence of attacks occurring at new locations,
or relapse of symptoms for locations with beginning of relief of
symptoms at 4 hours or less according to responses to questions 1
and 2 of the TEQ.
Safety was monitored in all patients. Immunogenicity (IgM and
IgG antibodies against rhC1INH, and antibodies against host-
related impurities [HRI]) was tested on samples obtained at
screening, before treatment, and at days 28 and 90. Antirabbit
dander IgE was tested on samples collected at screening and at day
28 using a validated, commercially available system (ImmunoCAP,
Phadia, Sweden; or equivalent). Predefined cutoff values in ELISA
for anti-HRI and for anti-C1INH antibodies of IgM and IgG were
more than 100%, more than 50%, and more than 15%, respec-
tively. These cutoff levels were set on the basis of ELISA testing
results (mean þ 3 SD) for plasma samples from healthy volunteer
subjects and patients with HAE who had never been treated with
rhC1INH.
Statistical analyses
All patients received rhC1INH in the OLE phase were included
in the safety analysis. All patients treated with rhC1INH in the OLE
phase with any available efficacy data comprised the OLE intent-to-
treat analysis set. For patients who received rhC1INH in the RCT
phase (either as their randomized treatment or as open-label rescue
medication), the first attack in the OLE phase was labeled as attack
2. For patients who received saline in the RCT phase, the first attack
in the OLE phase was labeled as attack 1. All analysis data sets and
outputs were produced using SAS (version 9.1 or higher).
Summary statistics including the number of patients, mean, and
SD were presented as continuous variables. For categorical variables,
the absolute counts (n) and percentages (%) of patients with data
were presented per category. All percentages were presented to
integer values. For time-to-event analyses, time to beginning of relief
of symptoms, and time to minimal symptoms, the median time to
event (with 95% CI) was presented for each attack and for all at-
tacks, and Kaplan-Meier plots were presented for each attack only.
The cumulative number of patients with beginning of relief of
symptoms at each time point was summarized using counts and
percentages. TEQ results at each time point were summarized by
attack using counts and percentages for the primary attack location.
The overall VAS score was presented by attack number. The IS at
each time point and the point change from baseline for all post-
baseline time points were summarized as continuous variables and by
counts and percentages and summarized by attack. The number of
patients who received a second rhC1INH dose was summarized
using counts and percentages by attack number.RESULTS
Forty-four patients were treated for 224 HAE attacks in the
OLE phase. Of the 44 patients, 24 (55%) had been randomizedto receive rhC1INH and 20 (45%) had been randomized to the
saline group during the RCT phase. Eight patients randomized
to saline had received rhC1INH as rescue medication during the
RCT phase. Thus, for 32 patients, the first OLE-phase HAE
attack was labeled as attack 2, and for the remaining 12, the first
OLE-phase attack was labeled as attack 1. Thirty-nine patients
completed the study. Two patients withdrew consent, 1 dis-
continued for pregnancy, 1 discontinued as a result of moving,
and 1 patient withdrew because of noncompliance.
Baseline characteristics are summarized in Table I. Most of the
patients were white (95%), and there was a higher proportion of
female patients (26 of 44 [59%]) in the study. Table I presents the
overall VAS scores at baseline for attacks 1 to 5 and the primary
anatomical locations of individual attacks. The most common
anatomical locations of the HAE attacks were abdominal (45%)
and peripheral (41%) sites, similar to the real-world distribution of
attacks reported by patients and physicians.17,18
A total of 215 of 224 attacks (96%) were treated with a single
50-IU/kg dose of rhC1INH, and no increase in dose was needed
for treatments of repeat attacks.
TABLE II. Time to beginning of relief of symptoms at the primary attack location (with continued relief at subsequent assessment)
Endpoint
Median time to beginning of relief (min) (95% CI)
Attack 1* Attack 2 Attack 3 Attack 4 Attack 5 All attacks
Patients, n 11 36 28 23 18 44
TEQ (questions 1 and 2, with persistence)† 90.0 (33-212) 76.0 (60-105) 134.0 (75-150) 76.5 (58-150) 62.5 (48-90) 75.0 (69-89)
Patients, n 12 40 32 25 20 44
VAS score decrease 20 mm, with persistence 105.0 (100-211) 75.0 (60-90) 105.0 (62-148) 93.0 (74-120) 90.0 (40-120) 90.0 (77-100)
Patients, n 12 40 32 25 20 44
IS decrease 1 point 87.0 (60-90) 72.5 (45-88) 60.0 (60-90) 60.0 (45-90) 75.5 (34-105) 74.5 (60-76)
*Attack 1 from OLE phase only.
†The TEQ was not performed for 17 of the 224 total attacks.
FIGURE 2. Kaplan-Meier plot of time to beginning of symptom relief (based on the treatment effect questions 1 and 2, with persistence)
at the primary attack location—OLE ITTanalysis set. ITT, intention to treat.
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Table II summarizes the time to onset of symptom relief after
rhC1INH treatment by attack number and for all attacks using
the TEQ, VAS, and IS assessment instruments. Data are pro-
vided by attack number up to attack 5 because there were a
limited number of patients with more than 5 treated attacks.
Patients with more than 5 treated attacks are included in the “all
attacks” column. The overall median time to relief of symptoms
was 75.0 minutes (95% CI, 69.0-89.0) for all 5 attacks using the
TEQ, and the median time to beginning of relief of symptoms
for each of the first 5 attacks ranged from 62.5 to 134 minutes.
Median times to beginning of relief of symptoms were similar
when assessed using the VAS and the IS, and were 90.0 and 74.5
minutes, respectively.
Kaplan-Meier estimates for time to beginning of symptom
relief are shown in Figure 2 based on the TEQ. Treatment with
rhC1INH led to consistent onset of symptom relief for repeat
attacks. Results were similar for the Kaplan-Meier estimates
based on the VAS scores (data not shown).
The proportion of attacks with persistent relief at 4 hours after
rhC1INH treatment is given for individual attacks 1 to 5 and for
all attacks (n ¼ 224) during the OLE phase of the study in
Table III. TEQ assessment was performed for 207 of 224attacks, and the overall response rate was 84% (174 of 207). The
response rate was at least 75% for each of the first 5 attacks
regardless of the assessment method used. Overall rates of
response were 79% (177/224) and 87% (184/224) based on the
VAS and IS assessments, respectively.
The times to minimal symptoms based on TEQ, VAS, and IS
are given in Table IV for the first 3 attacks and overall. The
overall median time was 303 minutes for all attacks based on the
TEQ with a range of 211 to 367 minutes. Median times were
similar across efficacy instruments and were 243 and 244 mi-
nutes for all attacks as assessed by VAS and IS instruments,
respectively. Kaplan-Meier plots of time to minimal symptoms
for the first 3 attacks are shown in Figure 3. Times to minimal
symptoms were similar for repeat attacks. Kaplan-Meier results
were similar based on VAS scores (data not shown).
For the first 3 attacks, no patient in the OLE phase had an
attack at a new location within 24 hours of treatment. In addi-
tion, relapse (defined as symptoms initially improved within 4
hours, but recurred within 24 hours according to responses to
questions 1 and 2 of the TEQ) was infrequent. None of the 39
patients with a response for the first attack during the OLE phase
had a relapse, 2 of 33 (6%) had a relapse after the second attack,
and 1 of 18 (6%) had a relapse after the third attack.
TABLE III. Proportion of attacks responding* to rhC1INH
Endpoint
Attacks with response* to rhC1INH, n (%)
Attack 1† Attack 2 Attack 3 Attack 4 Attack 5 Total attacks
Attacks, n 11 36 28 23 18 207z
TEQ (questions 1 and 2, with persistence) 9 (82) 33 (92) 24 (86) 18 (78) 17 (94) 174 (84)
Attacks, n 12 40 32 25 20 224
VAS score decrease 20 mm, with persistence 9 (75) 33 (83) 25 (78) 19 (76) 16 (80) 177 (79)
Attacks, n 12 40 32 25 20 224
IS decrease 1 point 11 (92) 38 (95) 29 (91) 25 (100) 17 (85) 194 (87)
*Response defined as beginning of relief by 4 h.
†Attack 1 from OLE phase only.
zThe TEQ was not performed for 17 of the 224 total attacks.
TABLE IV. Time to minimal symptoms at the primary attack location for the first 3 attacks and for all attacks
Assessment
Median time to minimal symptoms (min) (95% CI)
Attack 1* Attack 2 Attack 3 All attacks
Patients, n 11 36 21 44
TEQ (question 3) 243.0 (76-1440) 304.0 (150-719) 272.0 (210-480) 303.0 (211-367)
Patients, n 12 40 25 44
All VAS score <20 mm 290.0 (120-1440) 240.0 (120-300) 268.0 (181-480) 243.0 (150-272)
Patients, n 12 40 25 44
All IS 1 point 244.0 (117, -) 180.0 (120-301) 268.0 (181, -) 244.0 (181-300)
-, Not estimable.
*Attack 1 from OLE phase only.
FIGURE 3. Kaplan-Meier plot of time to minimal symptoms (based on the treatment effect question 3) at the primary attack location—
OLE ITTanalysis set. ITT, Intention to treat.
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Twelve of 44 patients (27%) reported treatment-emergent
adverse events within 72 hours of completion of infusion that were
mild ormoderate in severity and similar to events reported during the
RCT phase of the study.16 No patient discontinued treatment
because of an adverse event. Adverse events occurring in 2 or more
(5%) patients within 72 hours of the completion of rhC1INH
infusion were nasopharyngitis, elevated D-dimer concentration,
headache, and cough. D-dimer concentrations were elevated at the
time of an acute attack and generally decreased by day 7.Fifteen mild or moderate adverse events in 4 patients were
considered treatment-related: flatulence (4 events), diarrhea (3
events), increased lacrimation (2 events), back pain, chills, fa-
tigue, nasopharyngitis, pruritus, and rash (1 event each).
Five patients had 9 severe treatment-emergent adverse events
that resolved and were not considered to be related to study
treatment: 1 patient with 3 events of abdominal pain, 1 patient
with 2 events of headache and 1 event of vomiting, and 3
separate patients with a report of animal bite, facial HAE attack,
or increased blood pressure. There was 1 serious event reported
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days after the administration of rhC1INH.
There was no increase in the frequency of adverse events with
increasing numbers of rhC1INH administrations: following
attack 1, 7 of 12 (58%) patients experienced adverse events
compared with 16 of 40 (40%), 10 of 32 (31%), 8 of 25 (32%),
and 8 of 20 (40%) patients following attacks 2, 3, 4, and 5,
respectively. No pattern of emerging adverse events was observed
for multiple attacks.
No neutralizing anti-C1INH antibodies were observed in any
patient after repeat treatment with rhC1INH. Five patients had
confirmed anti-rhC1INH antibodies of the IgG isotype. One
patient had elevated IgG antibodies during attacks 2, 4, and 5, 1
during attacks 2, 13, and 15, 1 during attacks 3 to 17, 1 during
attack 5 only, and 1 patient during attacks 13 and 14. Similar
efficacy results were observed for each of these patients in the
presence and absence of positive antibody results, suggesting no
effect of antibodies on the efficacy of rhC1INH in treating acute
angioedema attacks. Three patients experienced adverse events of
rash, 2 of whom tested positive for HRI antibodies. No other
patients reported any adverse event suggestive of a symptomatic
hypersensitivity reaction. No anaphylactic reactions were
observed in any patient, and there was no induction of IgE an-
tibodies to rabbit dander epithelium.
There were no clinically relevant mean changes or shifts from
baseline in hematology or biochemistry parameters or vital signs.
No thrombotic events occurred in any patient during the study.DISCUSSION
rhC1INH is a novel therapy for HAE that has been shown in
RCTs to be an effective and safe treatment for acute HAE at-
tacks. The present OLE-phase data demonstrate that rhC1INH
provides persistent relief of symptoms for repeat HAE attacks in
a large population of patients with HAE with diverse attack lo-
cations. Most of the attacks had onset of relief within 4 hours of
rhC1INH treatment. Treatment with rhC1INH was well
tolerated, and the incidence of symptom relapse was low for
initial and subsequent attacks. Almost all attacks were treated
with only a single dose of rhC1INH. There were no increases in
adverse events, or additional dose requirements with treatments
for multiple attacks. These results indicate that rhC1INH effi-
cacy and safety are maintained when administered for repeated
HAE attacks.
The study planned for the administration of a single
rhC1INH dose of 50 IU/kg for each attack, with additional
doses permitted as early as 1 hour after the completion of infu-
sion of the first dose at the discretion of the investigator on the
basis of assessment of the patient’s response and symptoms. The
vast majority (96%) of patients required only 1 dose of
rhC1INH. Similarly, the relapse rate for patients in the OLE
phase who responded to a single dose of rhC1INH was low, 0%
after the first attack and 6% after the second or third attack.
Relapse within 24 hours of treatment for patients responding to a
single dose of rhC1INH has been low in all clinical trials to
date.13-16 In addition, the incidence of recurrence of symptoms
after rhC1INH treatment was low. In an analysis of patients
pooled from 2 RCTs and their OLEs, 93% (260 of 280) of the
patients with attacks treated with rhC1INH remained free of
recurrence or new attack symptoms within 3 days after
treatment.19The results of this study are consistent with those previously
observed in RCTs reported by Zuraw et al13 in which 95% of
rhC1INH-treated patients (either 50 IU/kg or 100 IU/kg)
experienced relief of symptoms within 4 hours with efficacy
maintained for repeat attacks. Previous OLE studies also evalu-
ated rhC1INH (50 IU/kg) treatment for repeated attacks.14,15 In
these open-label studies, efficacy (time to beginning of relief of
symptoms) was consistent with that described in the present
study (90 min vs 152 min for saline) and was comparable across
multiple treated attacks. rhC1INH was well tolerated, with no
increase in the incidence of adverse events on repeated treatment.
In contrast to these previous RCT and open-label studies, the
present study (and the parent RCT16) used the TEQ-based ef-
ficacy assessment, which was used as the primary patient-
reported efficacy assessment tool at the request of regulatory
authorities. Patient-reported outcomes form the basis of efficacy
tools used in HAE acute treatment studies because the goal of
treatment is symptom relief rather than cure.20 VAS instruments
have been widely used in assessing HAE symptom severity, and
content validity has been demonstrated.21 Comparisons of results
of the primary analysis using the TEQ in the present study with
analysis using the VAS and with those of earlier studies using
validated VAS instruments13-15 show consistency across efficacy
instruments. It is also important to note that investigator as-
sessments of symptom relief using the IS were concordant with
patient self-assessments of efficacy in the present study.
Treatment with rhC1INH for repeat HAE attacks was well
tolerated, with a favorable overall safety profile. The most
common events within 72 hours of the completion of infusion
were mild or moderate headache, cough, nasopharyngitis, and
increase in fibrin-D-dimer level. Fibrin D-dimer levels were
elevated at presentation during an attack and before treatment
with rhC1INH in almost all patients, and typically returned to
normal levels within 7 days, reflecting no increased risk for
thromboembolism after rhC1INH treatment. There was no in-
crease in the percentage of patients with adverse events after
treatment for repeat attacks, and the profile of adverse events was
similar across attacks. There were no thrombotic events observed,
and no anaphylactic reactions occurred. The incidences of anti-
bodies to rhC1INH or HRI were low, with no impact on clinical
efficacy or safety, confirming the absence of neutralizing anti-
bodies. In an integrated analysis of immunogenicity findings
from clinical trials, Hack et al22 evaluated 155 patients treated
with 424 doses of rhC1INH and reported that no patient
developed neutralizing antibodies after repeated treatments.
There are several strengths to note regarding this study.
Consistent with the patient population in clinical practice, the
present study enrolled patients with HAE who were experiencing
moderate to severe angioedema attacks across a real-world dis-
tribution of attack locations.17,18 Inclusion of patients with any
affected location is important given recent treatment guidelines
advising early treatment of all attacks regardless of location or
severity.5,6 The present study also demonstrated good agreement
across efficacy instruments, and the results analyzed using the
TEQ were consistent with those observed using the validated
VAS. In addition, investigator assessments of symptom relief
were concordant with patient assessments. The study was
limited, however, by the open-label design and lack of a control
group, but efficacy results were consistent with those reported in
RCT and other OLE studies of rhC1INH for acute HAE
attacks.
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A single 50-IU/kg dose of rhC1INH was effective in
improving symptoms of repeat HAE attacks at all attack loca-
tions. rhC1INH had a positive safety profile. There was no in-
crease or change in the adverse event profile with rhC1INH
treatments for repeat attacks. rhC1INH treatment provided
rapid and sustained symptom improvement with a low rate of
symptom relapse. The present study supports repeated use of
rhC1INH for the treatment of recurring attacks in patients with
HAE.
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